Do vaccines work as well in people with weak immune systems? new study investigates
NCT ID NCT04952766
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study looked at how well the Pfizer COVID-19 vaccine triggers an immune response in 196 adults with weakened immune systems (due to conditions like kidney transplant, cancer, or HIV) compared to healthy adults. Researchers measured antibody levels and their ability to neutralize the virus over six months. The goal was to understand if immunocompromised people get the same protection from the vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- BNT162b2 (Pfizer-BioNTech COVID-19 vaccine)
- What this could lead to
- If successful, this study could show how well the COVID-19 vaccine protects immunocompromised people, helping tailor vaccination strategies for them.
- What could go wrong
- This is a completed observational study, not a treatment trial. It measures immune response but does not test a new therapy, so it won't directly change care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
CHU Orléans
Orléans, 45067, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A good Night's sleep: could a simple program ease Cancer's toll on rest?
- Can specially trained immune cells flush out hidden HIV?
- Can we decode the different types of pain in multiple sclerosis?
- Could sitting up make radiation therapy more comfortable?
- Can a blood pressure pill slow MS disability?
- Can we predict dangerous side effects when combining radiation and immunotherapy?